DelveInsight’s, “Neonatal Fc Receptor Antagonists – Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Neonatal Fc Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Neonatal Fc Receptor Antagonists: Overview
The neonatal Fc receptor (also FcRn, IgG receptor FcRn large subunit p51, or Brambell receptor) is a protein that in humans is encoded by the FCGRT gene. It is an Fc receptor which is similar in structure to the MHC class I molecule and also associates with beta-2-microglobulin. Several autoimmune disorders are caused by the binding of IgG to self antigens. Since FcRn extends IgG half-life in the circulation, it can also confer long half-lives on these pathogenic antibodies and promote autoimmune disease. Therapies seek to disrupt the IgG-FcRn interaction to increase the clearance of disease-causing IgG autoantibodies from the body. More recent approaches involve the strategy of blocking the binding of IgG to FcRn by injecting antibodies that bind with high affinity to this receptor through their Fc region or variable regions. Fc fragments or antibodies are currently being used in clinical trials as treatments for antibody-mediated autoimmune diseases such as primary immune thrombocytopenia and myasthenia gravis.
"Neonatal Fc Receptor Antagonists - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neonatal Fc Receptor Antagonists pipeline landscape is provided which includes the disease overview and Neonatal Fc Receptor Antagonists treatment guidelines. The assessment part of the report embraces, in depth Neonatal Fc Receptor Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neonatal Fc Receptor Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Neonatal Fc Receptor Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Neonatal Fc Receptor Antagonists.
This segment of the Neonatal Fc Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neonatal Fc Receptor Antagonists Emerging Drugs
Efgartigimod: Argenx
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod binds to the neonatal Fc receptor (FcRn), which is widely expressed throughout the body and plays a central role in rescuing IgG antibodies from degradation. Blocking FcRn reduces IgG antibody levels representing a logical potential therapeutic approach for several autoimmune diseases. Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. If approved, efgartigimod will be the first-and-only approval of an FcRn antagonist , Prescription Drug User Fee Act (PDUFA) target action date is December 17, 2021. Pre-approval access program opened in U.S. for efgartigimod for eligible people living with gMG.
Further product details are provided in the report……..
This segment of the report provides insights about the different Neonatal Fc Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Neonatal Fc Receptor Antagonists
There are approx. 3+ key companies which are developing the therapies for Neonatal Fc Receptor Antagonists. The companies which have their Neonatal Fc Receptor Antagonists drug candidates in the most advanced stage, i.e. preregistration include Argenx.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Neonatal Fc Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neonatal Fc Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neonatal Fc Receptor Antagonists drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Neonatal Fc Receptor Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Preregistration)
Efgartigimod: Argenx
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Neonatal Fc Receptor Antagonists Key Companies
Neonatal Fc Receptor Antagonists Key Products
Neonatal Fc Receptor Antagonists- Unmet Needs
Neonatal Fc Receptor Antagonists- Market Drivers and Barriers
Neonatal Fc Receptor Antagonists- Future Perspectives and Conclusion
Neonatal Fc Receptor Antagonists Analyst Views
Neonatal Fc Receptor Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for Neonatal Fc Receptor Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Neonatal Fc Receptor Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Argenx
• HanAll Biopharma
• UCB Biopharma
• Janssen Pharmaceutical
